ESMO Congress 2026 will feature updated findings on KRAS inhibitors, bispecific T-cell engagers, and other key modalities in the lung cancer field.
News|Articles|October 25, 2026
Top Takeaways for Renal Cell Carcinoma From The 2026 ESMO Congress
Author(s)Cancer Network Staff
Fact checked by: Roman Fabbricatore, Russ Conroy
Triplets did not beat pembrolizumab plus lenvatinib in frontline RCC, while belzutifan plus lenvatinib and perioperative pembrolizumab showed benefit.
Advertisement
Advertisement
At the
Related to this article
Experts preview 6 breast cancer trials to watch at ESMO 2026, including KEYNOTE-B49, evERA, DESTINY-Breast11, SWITCH, PANKU-Breast01, and VIKTORIA-1.
An expert highlights OrigAMI-4, iza-bren plus pembrolizumab, GORTEC IDEAL, and HexAgon-HN ahead of the ESMO Congress 2026.
Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC.
Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.
Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Advertisement
Advertisement